Innate Pharma: management transactions · France · AMF

About Innate Pharma

Innate Pharma is a French biotechnology company listed on Euronext Paris under the ticker IPH and also traded on Nasdaq as IPHA. Founded in Marseille in 1999, the company has built its strategy around immuno-oncology, with a focus on developing innovative cancer therapies that harness the immune system. Its business model is centered on discovery, clinical development, and the monetization of proprietary and partnered assets, with a long-term objective of creating value through a differentiated pipeline rather than through commercialized products. Innate Pharma is best described as a clinical-stage biopharmaceutical company with a pipeline structured around several core programs. Its most advanced internal asset is lacutamab, an antibody targeting KIR3DL2, being developed in cutaneous T-cell lymphomas and certain hematologic malignancies. The company is also advancing IPH4502, a nectin-4 antibody-drug conjugate, together with next-generation ADC and multispecific antibody programs. Among its notable partnered assets are monalizumab, co-developed with AstraZeneca, and IPH5201, another AstraZeneca-partnered oncology program. This blend of internal innovation and major pharmaceutical partnerships is central to Innate Pharma’s industrial and financial positioning. The company has established its scientific reputation through expertise in innate immune biology, especially natural killer cells, and through its ability to identify novel oncology targets. Its R&D approach emphasizes first-in-class or best-in-class mechanisms and biomarker-driven development in order to improve patient selection and clinical probability of success. Over time, Innate Pharma has also expanded its credibility through collaborations with major pharma groups, particularly AstraZeneca. In 2025, Sanofi subscribed to a capital increase of nearly €15 million, underlining continued external interest in the company’s platform and pipeline. Geographically, Innate Pharma remains anchored in Marseille while operating internationally through its clinical trial network, business partnerships, and U.S. market presence. The company has recently reiterated a clear prioritization strategy, concentrating resources on its highest-value clinical assets. As of December 31, 2025, cash and cash equivalents stood at €44.8 million, with management indicating a cash runway through the end of Q3 2026. Innate Pharma therefore remains a flagship French biotech name: scientifically ambitious, clinically exposed, and highly leveraged to trial readouts, partnering opportunities, and the successful translation of its pipeline into long-term shareholder value.